0001766140
false
0001766140
2023-09-05
2023-09-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 5, 2023
Unicycive Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40582 |
|
81-3638692 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer
|
incorporation or organization) |
|
|
|
Identification No.) |
4300 El Camino Real, Suite 210
Los Alto, CA 94022
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (650) 351-4495
(Former name or former address, if changed since
last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
Common Stock |
|
UNCY |
|
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On September 5, 2023, Unicycive Therapeutics, Inc.
(the “Company”) appointed Sara Kenkare-Mitra as an independent director.
Sara Kenkare-Mitra, PhD is currently President and Head of Research
and Development at Alector where she leads all aspects of the company’s R&D efforts in neurodegeneration, including oversight
of the research, development, clinical, manufacturing, regulatory, and related functions. Prior to joining Alector, Dr. Kenkare-Mitra
held roles of increasing responsibility at Genentech over the course of 23 years serving most recently as Senior Vice President, Development
Sciences in Genentech’s research and early development unit. During her tenure at Genentech, she led a large, integrated
global organization of approximately 650 employees, and played a key role in the filing of more than 100 Investigational New Drug
(IND)/clinical trial applications around the world, and the approval of 11 medicines for diverse diseases, including cancers and neurological
diseases. Her team also enabled the successful development and approval of over 15 companion diagnostics.
Item 8.01 Other Events.
On September 6, 2023, the Company issued a press release announcing
that Dr. Kenkare-Mitra was appointed a director of the Company. A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:
September 6, 2023
|
UNICYCIVE THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Shalabh Gupta |
|
|
Shalabh Gupta |
|
|
Chief Executive Officer |
2
Exhibit 99.1
Unicycive Therapeutics Strengthens Board of Directors with Appointment of
Sara Kenkare-Mitra, PhD
- Appointment adds decades of drug development
experience from a seasoned executive –
LOS ALTOS, California,
September 6, 2023 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for
patients with kidney disease (the “Company or “Unicycive”), today announced the appointment of Sara Kenkare-Mitra,
PhD to the Company’s Board of Directors, effective September 6, 2023. As a veteran of the
biotech and pharmaceutical industry, we believe Sara’s leadership and experience
in drug development spanning more than 25 years will significantly help bolster Unicycive’s future growth.
“We are thrilled to welcome
Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadership experience will make
an immediate impact here at Unicycive,” said Shalabh Gupta, MD, Chief Executive Officer. “Sara adds a broad skill set to our
Board with leadership expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory.
Importantly, she has played a key role in the filing of more than 100 investigational new drug (IND) and clinical trial applications and
worked on 11 drug approvals in multiple diseases. Sara’s appointment comes at a crucial time for Unicycive as we advance oxylanthanum
carbonate towards filing of a new drug application and prepare to file an IND for UNI-494.”
Dr. Kenkare-Mitra, added, “I am honored to join the Unicycive Board of Directors to help advance the company’s
purpose-driven strategy to solve the most pressing unmet medical needs in renal diseases. I look forward to helping Unicycive with my
expertise and experience in preclinical and clinical development and navigating the regulatory landscape as the organization advances
their assets.”
Sara Kenkare-Mitra,
PhD is currently President and Head of Research and Development at Alector where she leads all aspects of the company’s
R&D efforts in neurodegeneration, including oversight of the research, development, clinical, manufacturing, regulatory, and
related functions. Prior to joining Alector, Dr. Kenkare-Mitra held roles of increasing responsibility at Genentech over the course
of 23 years serving most recently as Senior Vice President, Development Sciences in Genentech’s research and early development
unit. During her tenure at Genentech, she led a large, integrated global
organization of approximately 650 employees, and played a key role in the filing of more than 100 Investigational New Drug
(IND)/clinical trial applications around the world, and the approval of 11 medicines for diverse diseases, including cancers and
neurological diseases. Her team also enabled the successful development and approval of over 15 companion diagnostics.
Dr. Kenkare-Mitra received her PhD in
Pharmaceutical Chemistry from the University of California, San Francisco (UCSF), where she also stayed on as a Post-Doctoral Fellow
in the school of medicine and also completed a Fellowship in Clinical Pharmacology before joining Genentech. Dr.
Kenkare-Mitra also holds adjunct faculty positions in the Department of Bioengineering and Therapeutic Sciences at UCSF
and at the University of the Pacific in Stockton. She is an elected member of the National Academy of Medicine (NAM) and
elected fellow of Association for the Advancement of Science (AAAS). She has been
widely recognized for her work and leadership in the industry with awards such as the American Association of Pharmaceutical
Scientists’ Alice E. Till Advancement of Women in Pharmaceutical Sciences Recognition, Endpoints’ 20 Most Extraordinary
Women in Biopharma, Fierce Pharma’s Fiercest Women in the Life Sciences, and the University of California, San
Francisco’s Distinguished Alumnus of the Year. She has served as a board member of the Genentech foundation and the
Association of Women in Science (AWIS).
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel
investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.
UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information,
please visit Unicycive.com.
Forward-looking statements
Certain statements in this press
release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified
using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or
other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements
are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual
events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical
trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive
of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that
could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition
and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation;
dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,
including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’
in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities
and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive
specifically disclaims any obligation to update any forward- looking statement, whether as a result of new information, future events
or otherwise.
Investor Contact:
ir@unicycive.com
(650) 900-5470
SOURCE: Unicycive Therapeutics, Inc.
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From Apr 2024 to May 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From May 2023 to May 2024